Viatris Inc
VTRS: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $98.00 | Rgfy | Bmgwtjsmr |
Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
Business Strategy and Outlook
Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin